09:48 AM EDT, 07/23/2024 (MT Newswires) -- Arcutis Biotherapeutics ( ARQT ) said Tuesday that it has submitted a supplemental new drug application to the US Food and Drug Administration for Zoryve foam 0.3% to treat adults and adolescents aged 12 and above with scalp and body psoriasis.

The submission is backed by positive results from a late-stage trial, a phase 2b study, and long-term data from the Zoryve cream program, the company said.

Price: 9.86, Change: +0.01, Percent Change: +0.10